

Supplementary Table S1. Comparison of pregnancy complications compared with control population

	SSA/Ro positive patients (N events/cases analysed (%))	controls/all (%)	p-value (OR; 95% CI)
IUGR	20/304 (6.6)	6/224 [§] (2.7)	NS
Preeclampsia	3/305 (1)	5/224 [§] (2.2)	NS
Pre-term (<37w)	49/305 (16.1)	401/3178* (12.6)	NS
Pre-term without CHB	42/297 (14.1)	401/3178* (12.6)	NS
Severe pre-term (<34w)	9/305 (2.9)	201/3178* (6.3)	0.025 (OR=0.45, 95% CI: 0.22–0.88)
Severe pre-term without CHB	8/297 (2.7)	201/3178* (6.3)	0.017 (OR=0.041, 95% CI: 0.20–0.84)
Gestational diabetes	15/305 (4.9)	12/224 [§] (5.3)	NS
Gestational hypertension	8/305 (2.6)	11/224 [§] (4.9)	NS
SGA	31/280 (11.1)	21/177 [§] (11.9)	NS
Caesarean section	130/286 (45.5)	897/3065* (29.3)	< 0.0001 (OR= 2.01, 95% CI: 1.57–2.57)
Caesarean section without CHB	123/277 (44.4)	897/3065* (29.3)	< 0.0001 (OR=1.93, 95% CI: 1.50–2.47)
Live births/all fetuses	304/327 (92.9)	177/224 [§] (79)	< 0.0001 (OR=3.51, 95% CI: 2.06–5.97)
Foetal losses	23/327 (7)	45/224 [§] (20.1)	< 0.0001 (OR=0.30, 95% CI: 0.17–0.51)

IUGR: intra-uterine growth restriction; NS: not significant; SGA: small for gestational age was defined as birth weight in the <5th percentile for gestational age.

[§]Data from a multicentric study cohort of UCTD patients (18).

* Data from general obstetrical population of Spedali Civili of Brescia, year 2018.